S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
S&P 500   3,852.37 (+0.01%)
DOW   31,177.82 (-0.03%)
QQQ   324.17 (+0.12%)
AAPL   134.06 (+1.54%)
MSFT   224.10 (-0.11%)
FB   268.42 (+0.35%)
GOOGL   1,901.39 (+1.13%)
AMZN   3,307.18 (+1.34%)
TSLA   847.50 (-0.35%)
NVDA   530.70 (-0.74%)
BABA   261.51 (-1.50%)
CGC   33.68 (+0.15%)
GE   11.37 (-0.18%)
MU   82.80 (-0.84%)
AMD   88.60 (-0.17%)
NIO   56.38 (-2.30%)
T   28.84 (-0.41%)
F   11.27 (+3.78%)
ACB   11.46 (-0.69%)
BA   209.80 (-0.78%)
DIS   172.08 (-0.90%)
NFLX   581.56 (-0.82%)
GILD   67.42 (-0.84%)
Log in
NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$9.30
-0.42 (-4.32 %)
(As of 01/21/2021 09:34 AM ET)
Add
Compare
Today's Range
$8.87
Now: $9.30
$9.31
50-Day Range
$8.85
MA: $10.24
$12.60
52-Week Range
$3.14
Now: $9.30
$33.79
Volume130,190 shs
Average Volume9.36 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals logo

MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

579th out of 1,928 stocks

Surgical & Medical Instruments Industry

61st out of 170 stocks

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone858-410-3134
Employees190

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.11 million
Book Value$0.05 per share

Profitability

Net Income$-119,360,000.00
Net Margins-8,518.10%

Miscellaneous

Market Cap$1.58 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$9.30
-0.42 (-4.32 %)
(As of 01/21/2021 09:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

How has Inovio Pharmaceuticals' stock been impacted by Coronavirus?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INO shares have increased by 6.1% and is now trading at $8.88.
View which stocks have been most impacted by COVID-19
.

Is Inovio Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Inovio Pharmaceuticals?

Wall Street analysts have given Inovio Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inovio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Inovio Pharmaceuticals' CEO?

1,428 employees have rated Inovio Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Inovio Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.30. The biopharmaceutical company earned $0.24 million during the quarter, compared to analysts' expectations of $3.05 million. Inovio Pharmaceuticals had a negative net margin of 8,518.10% and a negative return on equity of 78.17%. The business's revenue for the quarter was down 72.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) EPS.
View Inovio Pharmaceuticals' earnings history
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

8 brokers have issued 1-year price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $12.88 in the next year. This suggests a possible upside of 45.0% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 52, Pay $1.31M)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 58, Pay $711.13k)
  • Dr. Jacqueline E. Shea Ph.D., Chief Operating Officer (Age 55, Pay $611.75k)
  • Dr. Laurent M. Humeau, Chief Scientific Officer (Age 54, Pay $572.16k)
  • Ben Matone, Director of Investor Relations
  • Mr. Jeffrey C. Richardson, VP of Communications & Strategic Relations
  • Mr. E. J. Brandreth, Sr. VP of Quality Assurance
  • Ms. Jessica C. Lee MS, MPH, Sr. VP of Clinical Operations & Global Integration
  • Dr. Prakash Bhuyan, Sr. VP of Clinical Devel.
  • Dr. Ami Shah Brown, Sr. VP of Regulatory Affairs

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%) and Allied Investment Advisors LLC (0.01%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau and Peter Kies.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Allied Investment Advisors LLC, and Pacer Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau.
View insider buying and selling activity for Inovio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $8.88.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $1.50 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 190 workers across the globe.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 858-410-3134 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.